{"id":496325,"date":"2020-07-15T19:50:01","date_gmt":"2020-07-15T19:50:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=496325"},"modified":"2020-07-15T19:50:01","modified_gmt":"2020-07-15T19:50:01","slug":"hemophilia-a-pipeline-assessment-key-companies-and-emerging-drugs","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hemophilia-a-pipeline-assessment-key-companies-and-emerging-drugs_496325.html","title":{"rendered":"Hemophilia A Pipeline Assessment, Key Companies And Emerging Drugs"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hemophilia A Pipeline Assessment, Key Companies And Emerging Drugs\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Hemophilia A Pipeline Assessment, Key Companies And Emerging Drugs\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Hemophilia A Pipeline Insight, 2020&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Hemophilia A market. <\/p>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s&nbsp;Hemophilia A Pipeline assessment part of the report embraces in-depth Hemophilia A commercial assessment and clinical assessment of the Hemophilia A pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hemophilia A collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Get FREE sample copy at:&nbsp;<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hemophilia-a-pipeline-insight\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/hemophilia-a-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hemophilia-a-pipeline-insight\" target=\"_blank\"><strong><span data-mce-mark=\"1\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/span><\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<img decoding=\"async\" title=\"Hemophilia-A-Pipeline-Assessment\" src=\"https:\/\/www.abnewswire.com\/uploads\/97342957f60393e6bfa8deb7651d0055.jpg\" alt=\"Hemophilia-A-Pipeline-Assessment\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><br \/>Key companies<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Biomarin Pharmaceutical<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Novo Nordisk<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Sanofi<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Pfizer<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Catalyst Biosciences<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>OPKO Biologics<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Spark Therapeutics<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Sangamo therapeutics&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>And many others<\/em><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Drug Covered<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Fitusiran<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Concizumab (NN7415)<\/em><\/p>\n<p style=\"text-align: justify;\"><em>Marstacimab (PF-06741086)<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Marzeptacog alfa<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Valoctocogene Roxaparvovec<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>BIVV001<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>SPK-8011<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>SB-525<\/em><\/p>\n<p style=\"text-align: justify;\"><em>&nbsp;And many others<\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-a-pipeline-insight\" target=\"_blank\"><strong><span data-mce-mark=\"1\">Hemophilia A Pipeline Analysis<\/span><\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">The report provides insights into:&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia A with aggregate therapies developed by each company for the same.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Hemophilia A treatment.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Hemophilia A key players<\/span><span data-mce-mark=\"1\"> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Hemophilia A market.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The Hemophilia Areport provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by <\/span><span data-mce-mark=\"1\">development stage, product type, route of administration, molecule type, and MOA type for Hemophilia A<\/span><span data-mce-mark=\"1\"> across the complete product development cycle, including all clinical and nonclinical stages.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">It comprises of detailed profiles of Hemophilia A therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Detailed Hemophilia A research and development progress and trial details, results wherever available, are also included in the pipeline study.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Coverage of dormant and discontinued pipeline projects along with the reasons if available across Hemophilia A.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Report highlights<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Hemophilia A.&nbsp;&nbsp;&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">In the coming years, the Hemophilia A market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">The companies and academics that are working to assess challenges and seek opportunities that could influence Hemophilia A R&amp;D. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">A detailed portfolio of major pharma players who are involved in fueling the Hemophilia A treatment market. Several potential therapies for Hemophilia A are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Hemophilia A market size in the coming years.&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Hemophilia A) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">1. Report Introduction<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">2. Hemophilia A&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">3. Hemophilia A Current Treatment Patterns<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">4. Hemophilia A &#8211; DelveInsight&#8217;s Analytical Perspective<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">5. Therapeutic Assessment<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">6. Hemophilia A Late Stage Products (Phase-III)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">7. Hemophilia A Mid Stage Products (Phase-II)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">8. Early Stage Products (Phase-I)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">9. Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">10. Inactive Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">11. Dormant Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">12. Hemophilia A Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">13. Hemophilia A Product Profiles<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">14. Hemophilia A Key Companies<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">15. Hemophilia A Key Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">16. Dormant and Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">17. Hemophilia A Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">18. Hemophilia A Future Perspectives<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">19. Hemophilia A Analyst Review&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">20. Appendix<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">21. Report Methodology<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-a2030-market\">Hemophilia A Market Insight, Epidemiology and Market Forecast -2030<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&#8217;s &#8220;Hemophilia A Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-a-epidemiology-forecast\"><span data-mce-mark=\"1\">Hemophilia A Epidemiology Forecast to 2030<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&#8217;s &#8216;Hemophilia A Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Hemophilia A epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">&nbsp;<\/span>&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Anuj Rawat<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hemophilia-a-pipeline-assessment-key-companies-and-emerging-drugs\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hemophilia-a-pipeline-assessment-key-companies-and-emerging-drugs\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research &#8220;Hemophilia A Pipeline Insight, 2020&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Hemophilia A market. DelveInsight&#8217;s&nbsp;Hemophilia A Pipeline assessment part of the report embraces in-depth Hemophilia A commercial &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hemophilia-a-pipeline-assessment-key-companies-and-emerging-drugs_496325.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-496325","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=496325"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496325\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=496325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=496325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=496325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}